Global Tumor Immunity PD-1 Inhibitors Market Research Report 2026(Status and Outlook)
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Tumor Immunity PD-1 Inhibitors competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.Tumor immunity PD-1 inhibitors are monoclonal antibody therapeutics that block the programmed cell death-1 (PD-1) pathway to restore antitumor immune responses and are widely used across solid tumors and hematologic malignancies. As recombinant protein medicines, their development and manufacturing rely on high-yield mammalian cell lines, cell culture media, single-use bioreactor consumables, chromatography resins, virus-removal filters, purification materials, formulation excipients, and aseptic filling and packaging components, supported by upstream systems for cell-line construction, critical reagents, analytical assays, and strict quality-control frameworks. These products require rigorous aseptic processing, GMP-compliant manufacturing, and cold-chain logistics, often accompanied by biomarker diagnostics and related medical devices as part of the clinical ecosystem. As a key pillar of modern immuno-oncology, PD-1 inhibitors have formed a complete value chain from research and process development to commercial-scale production, representing a major technological and commercial segment in the global cancer immunotherapy market.In 2024, global sales of the oncology immunotherapy PD-1 inhibitors reached 21.57 million vials, with an average price of USD 1,861 per vial, and corporate gross profit margins ranging between 60% and 70%.In recent years, tumor immunity PD-1 inhibitors have become an increasingly prominent component of global oncology treatment strategies, supported by expanding real-world evidence, guideline endorsements, and improved patient access. The competitive landscape has shifted from dominance by a few originator products to a multilayered market comprising originators, domestic innovators, biosimilars, and combination-therapy pipelines. Companies are differentiating through depth of indications, strength of clinical evidence, formulation innovation, and commercialization capabilities, resulting in a dynamic market evolving at high velocity.Future development will focus heavily on combination therapies and further expansion of clinical indications. As the boundaries of immunotherapy broaden, combinations with targeted agents, antibody-drug conjugates, cell therapies, oncolytic viruses, and cancer vaccines are being actively explored to improve response rates, overcome resistance, and enhance long-term survival. Increasing refinement of biomarker-driven patient selection will enable more precise and personalized treatment. Additionally, innovations such as subcutaneous formulations, long-acting versions, and prefilled delivery systems are expected to enhance convenience and reshape cost structures. Localized manufacturing capabilities in different regions will strengthen supply stability and shorten commercial delivery chains.The market's growth momentum is driven by multiple factors. Strengthening clinical evidence and broader physician adoption are accelerating therapeutic penetration across various tumor types. Regulatory acceleration, supportive reimbursement policies, and inclusion in public or private insurance systems are expanding patient access. Advanced bioprocessing technologies—including high-efficiency cell-line development, adoption of large-scale single-use systems, and intelligent analytical monitoring—are reducing manufacturing risks. The rise of CDMOs is enabling companies to scale more efficiently and bring products to market faster. Regionalization trends are increasing supply-chain resilience and stimulating local innovation.Despite the positive outlook, the field faces several challenges. Response heterogeneity across tumor types and patient populations limits effectiveness in certain settings, raising questions about the cost-effectiveness of some high-priced regimens. Immune-related adverse events require continuous management and patient education, adding complexity to long-term therapy. Growing competition is intensifying pricing pressure, as biosimilars and regional manufacturers reshape market economics and erode the commercial value of established products. Regulatory complexity, intellectual-property disputes, reimbursement delays, and geopolitical risks to global supply chains all contribute to uncertainty and represent key obstacles to the future development of PD-1 inhibitors.
The global Tumor Immunity PD-1 Inhibitors market size was estimated at USD 40158.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 11.20% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Tumor Immunity PD-1 Inhibitors market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Tumor Immunity PD-1 Inhibitors market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Tumor Immunity PD-1 Inhibitors market.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Tumor Immunity PD-1 Inhibitors Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Tumor Immunity PD-1 Inhibitors, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
The global Tumor Immunity PD-1 Inhibitors market size was estimated at USD 40158.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 11.20% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Tumor Immunity PD-1 Inhibitors market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Tumor Immunity PD-1 Inhibitors market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Tumor Immunity PD-1 Inhibitors market.
Global Tumor Immunity PD-1 Inhibitors Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
- Merck
- Novartis
- Sumitomo Dainippon Pharma
- Genentech (Roche)
- AstraZeneca
- Pfizer
- GSK
- Regeneron Pharmaceuticals
- Eli Lilly
- Jiangsu Hengrui Pharmaceuticals
- Curis Inc.
- Bristol-Myers Squibb
- Junshi Biosciences
- Innovent Biologics
- BeiGene
Market Segmentation (by Type)
- Pembrolizumab
- Nivolumab
- Cemiplimab
- Toripalimab
- Sintilimab
- Tislelizumab
- Camrelizumab
- Penpulimab
- Retifanlimab
- Zimberelimab
- by Application
Market Segmentation (by Application)
- Melanoma Treatment
- Non-Small Cell Lung Cancer Treatment
- Others
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Tumor Immunity PD-1 Inhibitors Market
Overview of the regional outlook of the Tumor Immunity PD-1 Inhibitors Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Tumor Immunity PD-1 Inhibitors Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Tumor Immunity PD-1 Inhibitors, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Tumor Immunity PD-1 Inhibitors
1.2 Key Market Segments
1.2.1 Tumor Immunity PD-1 Inhibitors Segment by Type
1.2.2 Tumor Immunity PD-1 Inhibitors Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 TUMOR IMMUNITY PD-1 INHIBITORS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Tumor Immunity PD-1 Inhibitors Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Tumor Immunity PD-1 Inhibitors Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 TUMOR IMMUNITY PD-1 INHIBITORS MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Tumor Immunity PD-1 Inhibitors Product Life Cycle
3.3 Global Tumor Immunity PD-1 Inhibitors Sales by Manufacturers (2020-2025)
3.4 Global Tumor Immunity PD-1 Inhibitors Revenue Market Share by Manufacturers (2020-2025)
3.5 Tumor Immunity PD-1 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Tumor Immunity PD-1 Inhibitors Average Price by Manufacturers (2020-2025)
3.7 Manufacturers’ Manufacturing Sites, Areas Served, and Product Types
3.8 Tumor Immunity PD-1 Inhibitors Market Competitive Situation and Trends
3.8.1 Tumor Immunity PD-1 Inhibitors Market Concentration Rate
3.8.2 Global 5 and 10 Largest Tumor Immunity PD-1 Inhibitors Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 TUMOR IMMUNITY PD-1 INHIBITORS INDUSTRY CHAIN ANALYSIS
4.1 Tumor Immunity PD-1 Inhibitors Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF TUMOR IMMUNITY PD-1 INHIBITORS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Tumor Immunity PD-1 Inhibitors Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy – April 2025
5.6.3 Global Trade Frictions and Their Impacts to Tumor Immunity PD-1 Inhibitors Market
5.7 ESG Ratings of Leading Companies
6 TUMOR IMMUNITY PD-1 INHIBITORS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Type (2020-2025)
6.3 Global Tumor Immunity PD-1 Inhibitors Market Size by Type (2020-2025)
6.4 Global Tumor Immunity PD-1 Inhibitors Price by Type (2020-2025)
7 TUMOR IMMUNITY PD-1 INHIBITORS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Tumor Immunity PD-1 Inhibitors Market Sales by Application (2020-2025)
7.3 Global Tumor Immunity PD-1 Inhibitors Market Size (M USD) by Application (2020-2025)
7.4 Global Tumor Immunity PD-1 Inhibitors Sales Growth Rate by Application (2020-2025)
8 TUMOR IMMUNITY PD-1 INHIBITORS MARKET SALES BY REGION
8.1 Global Tumor Immunity PD-1 Inhibitors Sales by Region
8.1.1 Global Tumor Immunity PD-1 Inhibitors Sales by Region
8.1.2 Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Region
8.2 Global Tumor Immunity PD-1 Inhibitors Market Size by Region
8.2.1 Global Tumor Immunity PD-1 Inhibitors Market Size by Region
8.2.2 Global Tumor Immunity PD-1 Inhibitors Market Size by Region
8.3 North America
8.3.1 North America Tumor Immunity PD-1 Inhibitors Sales by Country
8.3.2 North America Tumor Immunity PD-1 Inhibitors Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Tumor Immunity PD-1 Inhibitors Sales by Country
8.4.2 Europe Tumor Immunity PD-1 Inhibitors Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Tumor Immunity PD-1 Inhibitors Sales by Region
8.5.2 Asia Pacific Tumor Immunity PD-1 Inhibitors Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Tumor Immunity PD-1 Inhibitors Sales by Country
8.6.2 South America Tumor Immunity PD-1 Inhibitors Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Tumor Immunity PD-1 Inhibitors Sales by Region
8.7.2 Middle East and Africa Tumor Immunity PD-1 Inhibitors Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 TUMOR IMMUNITY PD-1 INHIBITORS MARKET PRODUCTION BY REGION
9.1 Global Production of Tumor Immunity PD-1 Inhibitors by Region(2020-2025)
9.2 Global Tumor Immunity PD-1 Inhibitors Revenue Market Share by Region (2020-2025)
9.3 Global Tumor Immunity PD-1 Inhibitors Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Tumor Immunity PD-1 Inhibitors Production
9.4.1 North America Tumor Immunity PD-1 Inhibitors Production Growth Rate (2020-2025)
9.4.2 North America Tumor Immunity PD-1 Inhibitors Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Tumor Immunity PD-1 Inhibitors Production
9.5.1 Europe Tumor Immunity PD-1 Inhibitors Production Growth Rate (2020-2025)
9.5.2 Europe Tumor Immunity PD-1 Inhibitors Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Tumor Immunity PD-1 Inhibitors Production (2020-2025)
9.6.1 Japan Tumor Immunity PD-1 Inhibitors Production Growth Rate (2020-2025)
9.6.2 Japan Tumor Immunity PD-1 Inhibitors Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Tumor Immunity PD-1 Inhibitors Production (2020-2025)
9.7.1 China Tumor Immunity PD-1 Inhibitors Production Growth Rate (2020-2025)
9.7.2 China Tumor Immunity PD-1 Inhibitors Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Merck
10.1.1 Merck Basic Information
10.1.2 Merck Tumor Immunity PD-1 Inhibitors Product Overview
10.1.3 Merck Tumor Immunity PD-1 Inhibitors Product Market Performance
10.1.4 Merck Business Overview
10.1.5 Merck SWOT Analysis
10.1.6 Merck Recent Developments
10.2 Novartis
10.2.1 Novartis Basic Information
10.2.2 Novartis Tumor Immunity PD-1 Inhibitors Product Overview
10.2.3 Novartis Tumor Immunity PD-1 Inhibitors Product Market Performance
10.2.4 Novartis Business Overview
10.2.5 Novartis SWOT Analysis
10.2.6 Novartis Recent Developments
10.3 Sumitomo Dainippon Pharma
10.3.1 Sumitomo Dainippon Pharma Basic Information
10.3.2 Sumitomo Dainippon Pharma Tumor Immunity PD-1 Inhibitors Product Overview
10.3.3 Sumitomo Dainippon Pharma Tumor Immunity PD-1 Inhibitors Product Market Performance
10.3.4 Sumitomo Dainippon Pharma Business Overview
10.3.5 Sumitomo Dainippon Pharma SWOT Analysis
10.3.6 Sumitomo Dainippon Pharma Recent Developments
10.4 Genentech (Roche)
10.4.1 Genentech (Roche) Basic Information
10.4.2 Genentech (Roche) Tumor Immunity PD-1 Inhibitors Product Overview
10.4.3 Genentech (Roche) Tumor Immunity PD-1 Inhibitors Product Market Performance
10.4.4 Genentech (Roche) Business Overview
10.4.5 Genentech (Roche) Recent Developments
10.5 AstraZeneca
10.5.1 AstraZeneca Basic Information
10.5.2 AstraZeneca Tumor Immunity PD-1 Inhibitors Product Overview
10.5.3 AstraZeneca Tumor Immunity PD-1 Inhibitors Product Market Performance
10.5.4 AstraZeneca Business Overview
10.5.5 AstraZeneca Recent Developments
10.6 Pfizer
10.6.1 Pfizer Basic Information
10.6.2 Pfizer Tumor Immunity PD-1 Inhibitors Product Overview
10.6.3 Pfizer Tumor Immunity PD-1 Inhibitors Product Market Performance
10.6.4 Pfizer Business Overview
10.6.5 Pfizer Recent Developments
10.7 GSK
10.7.1 GSK Basic Information
10.7.2 GSK Tumor Immunity PD-1 Inhibitors Product Overview
10.7.3 GSK Tumor Immunity PD-1 Inhibitors Product Market Performance
10.7.4 GSK Business Overview
10.7.5 GSK Recent Developments
10.8 Regeneron Pharmaceuticals
10.8.1 Regeneron Pharmaceuticals Basic Information
10.8.2 Regeneron Pharmaceuticals Tumor Immunity PD-1 Inhibitors Product Overview
10.8.3 Regeneron Pharmaceuticals Tumor Immunity PD-1 Inhibitors Product Market Performance
10.8.4 Regeneron Pharmaceuticals Business Overview
10.8.5 Regeneron Pharmaceuticals Recent Developments
10.9 Eli Lilly
10.9.1 Eli Lilly Basic Information
10.9.2 Eli Lilly Tumor Immunity PD-1 Inhibitors Product Overview
10.9.3 Eli Lilly Tumor Immunity PD-1 Inhibitors Product Market Performance
10.9.4 Eli Lilly Business Overview
10.9.5 Eli Lilly Recent Developments
10.10 Jiangsu Hengrui Pharmaceuticals
10.10.1 Jiangsu Hengrui Pharmaceuticals Basic Information
10.10.2 Jiangsu Hengrui Pharmaceuticals Tumor Immunity PD-1 Inhibitors Product Overview
10.10.3 Jiangsu Hengrui Pharmaceuticals Tumor Immunity PD-1 Inhibitors Product Market Performance
10.10.4 Jiangsu Hengrui Pharmaceuticals Business Overview
10.10.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
10.11 Curis Inc.
10.11.1 Curis Inc. Basic Information
10.11.2 Curis Inc. Tumor Immunity PD-1 Inhibitors Product Overview
10.11.3 Curis Inc. Tumor Immunity PD-1 Inhibitors Product Market Performance
10.11.4 Curis Inc. Business Overview
10.11.5 Curis Inc. Recent Developments
10.12 Bristol-Myers Squibb
10.12.1 Bristol-Myers Squibb Basic Information
10.12.2 Bristol-Myers Squibb Tumor Immunity PD-1 Inhibitors Product Overview
10.12.3 Bristol-Myers Squibb Tumor Immunity PD-1 Inhibitors Product Market Performance
10.12.4 Bristol-Myers Squibb Business Overview
10.12.5 Bristol-Myers Squibb Recent Developments
10.13 Junshi Biosciences
10.13.1 Junshi Biosciences Basic Information
10.13.2 Junshi Biosciences Tumor Immunity PD-1 Inhibitors Product Overview
10.13.3 Junshi Biosciences Tumor Immunity PD-1 Inhibitors Product Market Performance
10.13.4 Junshi Biosciences Business Overview
10.13.5 Junshi Biosciences Recent Developments
10.14 Innovent Biologics
10.14.1 Innovent Biologics Basic Information
10.14.2 Innovent Biologics Tumor Immunity PD-1 Inhibitors Product Overview
10.14.3 Innovent Biologics Tumor Immunity PD-1 Inhibitors Product Market Performance
10.14.4 Innovent Biologics Business Overview
10.14.5 Innovent Biologics Recent Developments
10.15 BeiGene
10.15.1 BeiGene Basic Information
10.15.2 BeiGene Tumor Immunity PD-1 Inhibitors Product Overview
10.15.3 BeiGene Tumor Immunity PD-1 Inhibitors Product Market Performance
10.15.4 BeiGene Business Overview
10.15.5 BeiGene Recent Developments
11 TUMOR IMMUNITY PD-1 INHIBITORS MARKET FORECAST BY REGION
11.1 Global Tumor Immunity PD-1 Inhibitors Market Size Forecast
11.2 Global Tumor Immunity PD-1 Inhibitors Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Tumor Immunity PD-1 Inhibitors Market Size Forecast by Country
11.2.3 Asia Pacific Tumor Immunity PD-1 Inhibitors Market Size Forecast by Region
11.2.4 South America Tumor Immunity PD-1 Inhibitors Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Tumor Immunity PD-1 Inhibitors by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Tumor Immunity PD-1 Inhibitors Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Tumor Immunity PD-1 Inhibitors by Type (2026-2035)
12.1.2 Global Tumor Immunity PD-1 Inhibitors Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Tumor Immunity PD-1 Inhibitors by Type (2026-2035)
12.2 Global Tumor Immunity PD-1 Inhibitors Market Forecast by Application (2026-2035)
12.2.1 Global Tumor Immunity PD-1 Inhibitors Sales (K MT) Forecast by Application
12.2.2 Global Tumor Immunity PD-1 Inhibitors Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Tumor Immunity PD-1 Inhibitors
1.2 Key Market Segments
1.2.1 Tumor Immunity PD-1 Inhibitors Segment by Type
1.2.2 Tumor Immunity PD-1 Inhibitors Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 TUMOR IMMUNITY PD-1 INHIBITORS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Tumor Immunity PD-1 Inhibitors Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Tumor Immunity PD-1 Inhibitors Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 TUMOR IMMUNITY PD-1 INHIBITORS MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Tumor Immunity PD-1 Inhibitors Product Life Cycle
3.3 Global Tumor Immunity PD-1 Inhibitors Sales by Manufacturers (2020-2025)
3.4 Global Tumor Immunity PD-1 Inhibitors Revenue Market Share by Manufacturers (2020-2025)
3.5 Tumor Immunity PD-1 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Tumor Immunity PD-1 Inhibitors Average Price by Manufacturers (2020-2025)
3.7 Manufacturers’ Manufacturing Sites, Areas Served, and Product Types
3.8 Tumor Immunity PD-1 Inhibitors Market Competitive Situation and Trends
3.8.1 Tumor Immunity PD-1 Inhibitors Market Concentration Rate
3.8.2 Global 5 and 10 Largest Tumor Immunity PD-1 Inhibitors Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 TUMOR IMMUNITY PD-1 INHIBITORS INDUSTRY CHAIN ANALYSIS
4.1 Tumor Immunity PD-1 Inhibitors Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF TUMOR IMMUNITY PD-1 INHIBITORS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Tumor Immunity PD-1 Inhibitors Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy – April 2025
5.6.3 Global Trade Frictions and Their Impacts to Tumor Immunity PD-1 Inhibitors Market
5.7 ESG Ratings of Leading Companies
6 TUMOR IMMUNITY PD-1 INHIBITORS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Type (2020-2025)
6.3 Global Tumor Immunity PD-1 Inhibitors Market Size by Type (2020-2025)
6.4 Global Tumor Immunity PD-1 Inhibitors Price by Type (2020-2025)
7 TUMOR IMMUNITY PD-1 INHIBITORS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Tumor Immunity PD-1 Inhibitors Market Sales by Application (2020-2025)
7.3 Global Tumor Immunity PD-1 Inhibitors Market Size (M USD) by Application (2020-2025)
7.4 Global Tumor Immunity PD-1 Inhibitors Sales Growth Rate by Application (2020-2025)
8 TUMOR IMMUNITY PD-1 INHIBITORS MARKET SALES BY REGION
8.1 Global Tumor Immunity PD-1 Inhibitors Sales by Region
8.1.1 Global Tumor Immunity PD-1 Inhibitors Sales by Region
8.1.2 Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Region
8.2 Global Tumor Immunity PD-1 Inhibitors Market Size by Region
8.2.1 Global Tumor Immunity PD-1 Inhibitors Market Size by Region
8.2.2 Global Tumor Immunity PD-1 Inhibitors Market Size by Region
8.3 North America
8.3.1 North America Tumor Immunity PD-1 Inhibitors Sales by Country
8.3.2 North America Tumor Immunity PD-1 Inhibitors Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Tumor Immunity PD-1 Inhibitors Sales by Country
8.4.2 Europe Tumor Immunity PD-1 Inhibitors Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Tumor Immunity PD-1 Inhibitors Sales by Region
8.5.2 Asia Pacific Tumor Immunity PD-1 Inhibitors Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Tumor Immunity PD-1 Inhibitors Sales by Country
8.6.2 South America Tumor Immunity PD-1 Inhibitors Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Tumor Immunity PD-1 Inhibitors Sales by Region
8.7.2 Middle East and Africa Tumor Immunity PD-1 Inhibitors Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 TUMOR IMMUNITY PD-1 INHIBITORS MARKET PRODUCTION BY REGION
9.1 Global Production of Tumor Immunity PD-1 Inhibitors by Region(2020-2025)
9.2 Global Tumor Immunity PD-1 Inhibitors Revenue Market Share by Region (2020-2025)
9.3 Global Tumor Immunity PD-1 Inhibitors Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Tumor Immunity PD-1 Inhibitors Production
9.4.1 North America Tumor Immunity PD-1 Inhibitors Production Growth Rate (2020-2025)
9.4.2 North America Tumor Immunity PD-1 Inhibitors Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Tumor Immunity PD-1 Inhibitors Production
9.5.1 Europe Tumor Immunity PD-1 Inhibitors Production Growth Rate (2020-2025)
9.5.2 Europe Tumor Immunity PD-1 Inhibitors Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Tumor Immunity PD-1 Inhibitors Production (2020-2025)
9.6.1 Japan Tumor Immunity PD-1 Inhibitors Production Growth Rate (2020-2025)
9.6.2 Japan Tumor Immunity PD-1 Inhibitors Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Tumor Immunity PD-1 Inhibitors Production (2020-2025)
9.7.1 China Tumor Immunity PD-1 Inhibitors Production Growth Rate (2020-2025)
9.7.2 China Tumor Immunity PD-1 Inhibitors Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Merck
10.1.1 Merck Basic Information
10.1.2 Merck Tumor Immunity PD-1 Inhibitors Product Overview
10.1.3 Merck Tumor Immunity PD-1 Inhibitors Product Market Performance
10.1.4 Merck Business Overview
10.1.5 Merck SWOT Analysis
10.1.6 Merck Recent Developments
10.2 Novartis
10.2.1 Novartis Basic Information
10.2.2 Novartis Tumor Immunity PD-1 Inhibitors Product Overview
10.2.3 Novartis Tumor Immunity PD-1 Inhibitors Product Market Performance
10.2.4 Novartis Business Overview
10.2.5 Novartis SWOT Analysis
10.2.6 Novartis Recent Developments
10.3 Sumitomo Dainippon Pharma
10.3.1 Sumitomo Dainippon Pharma Basic Information
10.3.2 Sumitomo Dainippon Pharma Tumor Immunity PD-1 Inhibitors Product Overview
10.3.3 Sumitomo Dainippon Pharma Tumor Immunity PD-1 Inhibitors Product Market Performance
10.3.4 Sumitomo Dainippon Pharma Business Overview
10.3.5 Sumitomo Dainippon Pharma SWOT Analysis
10.3.6 Sumitomo Dainippon Pharma Recent Developments
10.4 Genentech (Roche)
10.4.1 Genentech (Roche) Basic Information
10.4.2 Genentech (Roche) Tumor Immunity PD-1 Inhibitors Product Overview
10.4.3 Genentech (Roche) Tumor Immunity PD-1 Inhibitors Product Market Performance
10.4.4 Genentech (Roche) Business Overview
10.4.5 Genentech (Roche) Recent Developments
10.5 AstraZeneca
10.5.1 AstraZeneca Basic Information
10.5.2 AstraZeneca Tumor Immunity PD-1 Inhibitors Product Overview
10.5.3 AstraZeneca Tumor Immunity PD-1 Inhibitors Product Market Performance
10.5.4 AstraZeneca Business Overview
10.5.5 AstraZeneca Recent Developments
10.6 Pfizer
10.6.1 Pfizer Basic Information
10.6.2 Pfizer Tumor Immunity PD-1 Inhibitors Product Overview
10.6.3 Pfizer Tumor Immunity PD-1 Inhibitors Product Market Performance
10.6.4 Pfizer Business Overview
10.6.5 Pfizer Recent Developments
10.7 GSK
10.7.1 GSK Basic Information
10.7.2 GSK Tumor Immunity PD-1 Inhibitors Product Overview
10.7.3 GSK Tumor Immunity PD-1 Inhibitors Product Market Performance
10.7.4 GSK Business Overview
10.7.5 GSK Recent Developments
10.8 Regeneron Pharmaceuticals
10.8.1 Regeneron Pharmaceuticals Basic Information
10.8.2 Regeneron Pharmaceuticals Tumor Immunity PD-1 Inhibitors Product Overview
10.8.3 Regeneron Pharmaceuticals Tumor Immunity PD-1 Inhibitors Product Market Performance
10.8.4 Regeneron Pharmaceuticals Business Overview
10.8.5 Regeneron Pharmaceuticals Recent Developments
10.9 Eli Lilly
10.9.1 Eli Lilly Basic Information
10.9.2 Eli Lilly Tumor Immunity PD-1 Inhibitors Product Overview
10.9.3 Eli Lilly Tumor Immunity PD-1 Inhibitors Product Market Performance
10.9.4 Eli Lilly Business Overview
10.9.5 Eli Lilly Recent Developments
10.10 Jiangsu Hengrui Pharmaceuticals
10.10.1 Jiangsu Hengrui Pharmaceuticals Basic Information
10.10.2 Jiangsu Hengrui Pharmaceuticals Tumor Immunity PD-1 Inhibitors Product Overview
10.10.3 Jiangsu Hengrui Pharmaceuticals Tumor Immunity PD-1 Inhibitors Product Market Performance
10.10.4 Jiangsu Hengrui Pharmaceuticals Business Overview
10.10.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
10.11 Curis Inc.
10.11.1 Curis Inc. Basic Information
10.11.2 Curis Inc. Tumor Immunity PD-1 Inhibitors Product Overview
10.11.3 Curis Inc. Tumor Immunity PD-1 Inhibitors Product Market Performance
10.11.4 Curis Inc. Business Overview
10.11.5 Curis Inc. Recent Developments
10.12 Bristol-Myers Squibb
10.12.1 Bristol-Myers Squibb Basic Information
10.12.2 Bristol-Myers Squibb Tumor Immunity PD-1 Inhibitors Product Overview
10.12.3 Bristol-Myers Squibb Tumor Immunity PD-1 Inhibitors Product Market Performance
10.12.4 Bristol-Myers Squibb Business Overview
10.12.5 Bristol-Myers Squibb Recent Developments
10.13 Junshi Biosciences
10.13.1 Junshi Biosciences Basic Information
10.13.2 Junshi Biosciences Tumor Immunity PD-1 Inhibitors Product Overview
10.13.3 Junshi Biosciences Tumor Immunity PD-1 Inhibitors Product Market Performance
10.13.4 Junshi Biosciences Business Overview
10.13.5 Junshi Biosciences Recent Developments
10.14 Innovent Biologics
10.14.1 Innovent Biologics Basic Information
10.14.2 Innovent Biologics Tumor Immunity PD-1 Inhibitors Product Overview
10.14.3 Innovent Biologics Tumor Immunity PD-1 Inhibitors Product Market Performance
10.14.4 Innovent Biologics Business Overview
10.14.5 Innovent Biologics Recent Developments
10.15 BeiGene
10.15.1 BeiGene Basic Information
10.15.2 BeiGene Tumor Immunity PD-1 Inhibitors Product Overview
10.15.3 BeiGene Tumor Immunity PD-1 Inhibitors Product Market Performance
10.15.4 BeiGene Business Overview
10.15.5 BeiGene Recent Developments
11 TUMOR IMMUNITY PD-1 INHIBITORS MARKET FORECAST BY REGION
11.1 Global Tumor Immunity PD-1 Inhibitors Market Size Forecast
11.2 Global Tumor Immunity PD-1 Inhibitors Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Tumor Immunity PD-1 Inhibitors Market Size Forecast by Country
11.2.3 Asia Pacific Tumor Immunity PD-1 Inhibitors Market Size Forecast by Region
11.2.4 South America Tumor Immunity PD-1 Inhibitors Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Tumor Immunity PD-1 Inhibitors by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Tumor Immunity PD-1 Inhibitors Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Tumor Immunity PD-1 Inhibitors by Type (2026-2035)
12.1.2 Global Tumor Immunity PD-1 Inhibitors Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Tumor Immunity PD-1 Inhibitors by Type (2026-2035)
12.2 Global Tumor Immunity PD-1 Inhibitors Market Forecast by Application (2026-2035)
12.2.1 Global Tumor Immunity PD-1 Inhibitors Sales (K MT) Forecast by Application
12.2.2 Global Tumor Immunity PD-1 Inhibitors Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Tumor Immunity PD-1 Inhibitors Market Size by Type (M USD)
Table 4. Global Tumor Immunity PD-1 Inhibitors Market Size by Application
Table 5. Tumor Immunity PD-1 Inhibitors Market Size Comparison by Region (M USD)
Table 6. Global Tumor Immunity PD-1 Inhibitors Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Tumor Immunity PD-1 Inhibitors Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Tumor Immunity PD-1 Inhibitors Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Immunity PD-1 Inhibitors as of 2025)
Table 11. Global Market Tumor Immunity PD-1 Inhibitors Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers’ Manufacturing Sites, Areas Served
Table 13. Manufacturers’ Product Type
Table 14. Global Tumor Immunity PD-1 Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Tumor Immunity PD-1 Inhibitors Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Tumor Immunity PD-1 Inhibitors Sales by Type (K MT)
Table 27. Global Tumor Immunity PD-1 Inhibitors Market Size by Type (M USD)
Table 28. Global Tumor Immunity PD-1 Inhibitors Sales (K MT) by Type (2020-2025)
Table 29. Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Type (2020-2025)
Table 30. Global Tumor Immunity PD-1 Inhibitors Market Size (M USD) by Type (2020-2025)
Table 31. Global Tumor Immunity PD-1 Inhibitors Market Share by Type (2020-2025)
Table 32. Global Tumor Immunity PD-1 Inhibitors Price (USD/KG) by Type (2020-2025)
Table 33. Global Tumor Immunity PD-1 Inhibitors Sales (K MT) by Application
Table 34. Global Tumor Immunity PD-1 Inhibitors Market Size by Application
Table 35. Global Tumor Immunity PD-1 Inhibitors Sales by Application (2020-2025) & (K MT)
Table 36. Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Application (2020-2025)
Table 37. Global Tumor Immunity PD-1 Inhibitors Market Size by Application (2020-2025) & (M USD)
Table 38. Global Tumor Immunity PD-1 Inhibitors Market Share by Application (2020-2025)
Table 39. Global Tumor Immunity PD-1 Inhibitors Sales Growth Rate by Application (2020-2025)
Table 40. Global Tumor Immunity PD-1 Inhibitors Sales by Region (2020-2025) & (K MT)
Table 41. Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Region (2020-2025)
Table 42. Global Tumor Immunity PD-1 Inhibitors Market Size by Region (2020-2025) & (M USD)
Table 43. Global Tumor Immunity PD-1 Inhibitors Market Size by Region (2020-2025)
Table 44. North America Tumor Immunity PD-1 Inhibitors Sales by Country (2020-2025) & (K MT)
Table 45. North America Tumor Immunity PD-1 Inhibitors Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Tumor Immunity PD-1 Inhibitors Sales by Country (2020-2025) & (K MT)
Table 47. Europe Tumor Immunity PD-1 Inhibitors Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Tumor Immunity PD-1 Inhibitors Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific Tumor Immunity PD-1 Inhibitors Market Size by Region (2020-2025) & (M USD)
Table 50. South America Tumor Immunity PD-1 Inhibitors Sales by Country (2020-2025) & (K MT)
Table 51. South America Tumor Immunity PD-1 Inhibitors Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Tumor Immunity PD-1 Inhibitors Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa Tumor Immunity PD-1 Inhibitors Market Size by Region (2020-2025) & (M USD)
Table 54. Global Tumor Immunity PD-1 Inhibitors Production (K MT) by Region(2020-2025)
Table 55. Global Tumor Immunity PD-1 Inhibitors Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Tumor Immunity PD-1 Inhibitors Revenue Market Share by Region (2020-2025)
Table 57. Global Tumor Immunity PD-1 Inhibitors Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America Tumor Immunity PD-1 Inhibitors Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe Tumor Immunity PD-1 Inhibitors Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan Tumor Immunity PD-1 Inhibitors Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China Tumor Immunity PD-1 Inhibitors Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. Merck Basic Information
Table 63. Merck Tumor Immunity PD-1 Inhibitors Product Overview
Table 64. Merck Tumor Immunity PD-1 Inhibitors Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. Merck Business Overview
Table 66. Merck SWOT Analysis
Table 67. Merck Recent Developments
Table 68. Novartis Basic Information
Table 69. Novartis Tumor Immunity PD-1 Inhibitors Product Overview
Table 70. Novartis Tumor Immunity PD-1 Inhibitors Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. Novartis Business Overview
Table 72. Novartis SWOT Analysis
Table 73. Novartis Recent Developments
Table 74. Sumitomo Dainippon Pharma Basic Information
Table 75. Sumitomo Dainippon Pharma Tumor Immunity PD-1 Inhibitors Product Overview
Table 76. Sumitomo Dainippon Pharma Tumor Immunity PD-1 Inhibitors Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. Sumitomo Dainippon Pharma Business Overview
Table 78. Sumitomo Dainippon Pharma SWOT Analysis
Table 79. Sumitomo Dainippon Pharma Recent Developments
Table 80. Genentech (Roche) Basic Information
Table 81. Genentech (Roche) Tumor Immunity PD-1 Inhibitors Product Overview
Table 82. Genentech (Roche) Tumor Immunity PD-1 Inhibitors Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. Genentech (Roche) Business Overview
Table 84. Genentech (Roche) Recent Developments
Table 85. AstraZeneca Basic Information
Table 86. AstraZeneca Tumor Immunity PD-1 Inhibitors Product Overview
Table 87. AstraZeneca Tumor Immunity PD-1 Inhibitors Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 88. AstraZeneca Business Overview
Table 89. AstraZeneca Recent Developments
Table 90. Pfizer Basic Information
Table 91. Pfizer Tumor Immunity PD-1 Inhibitors Product Overview
Table 92. Pfizer Tumor Immunity PD-1 Inhibitors Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. Pfizer Business Overview
Table 94. Pfizer Recent Developments
Table 95. GSK Basic Information
Table 96. GSK Tumor Immunity PD-1 Inhibitors Product Overview
Table 97. GSK Tumor Immunity PD-1 Inhibitors Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. GSK Business Overview
Table 99. GSK Recent Developments
Table 100. Regeneron Pharmaceuticals Basic Information
Table 101. Regeneron Pharmaceuticals Tumor Immunity PD-1 Inhibitors Product Overview
Table 102. Regeneron Pharmaceuticals Tumor Immunity PD-1 Inhibitors Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 103. Regeneron Pharmaceuticals Business Overview
Table 104. Regeneron Pharmaceuticals Recent Developments
Table 105. Eli Lilly Basic Information
Table 106. Eli Lilly Tumor Immunity PD-1 Inhibitors Product Overview
Table 107. Eli Lilly Tumor Immunity PD-1 Inhibitors Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 108. Eli Lilly Business Overview
Table 109. Eli Lilly Recent Developments
Table 110. Jiangsu Hengrui Pharmaceuticals Basic Information
Table 111. Jiangsu Hengrui Pharmaceuticals Tumor Immunity PD-1 Inhibitors Product Overview
Table 112. Jiangsu Hengrui Pharmaceuticals Tumor Immunity PD-1 Inhibitors Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 113. Jiangsu Hengrui Pharmaceuticals Business Overview
Table 114. Jiangsu Hengrui Pharmaceuticals Recent Developments
Table 115. Curis Inc. Basic Information
Table 116. Curis Inc. Tumor Immunity PD-1 Inhibitors Product Overview
Table 117. Curis Inc. Tumor Immunity PD-1 Inhibitors Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 118. Curis Inc. Business Overview
Table 119. Curis Inc. Recent Developments
Table 120. Bristol-Myers Squibb Basic Information
Table 121. Bristol-Myers Squibb Tumor Immunity PD-1 Inhibitors Product Overview
Table 122. Bristol-Myers Squibb Tumor Immunity PD-1 Inhibitors Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 123. Bristol-Myers Squibb Business Overview
Table 124. Bristol-Myers Squibb Recent Developments
Table 125. Junshi Biosciences Basic Information
Table 126. Junshi Biosciences Tumor Immunity PD-1 Inhibitors Product Overview
Table 127. Junshi Biosciences Tumor Immunity PD-1 Inhibitors Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 128. Junshi Biosciences Business Overview
Table 129. Junshi Biosciences Recent Developments
Table 130. Innovent Biologics Basic Information
Table 131. Innovent Biologics Tumor Immunity PD-1 Inhibitors Product Overview
Table 132. Innovent Biologics Tumor Immunity PD-1 Inhibitors Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 133. Innovent Biologics Business Overview
Table 134. Innovent Biologics Recent Developments
Table 135. BeiGene Basic Information
Table 136. BeiGene Tumor Immunity PD-1 Inhibitors Product Overview
Table 137. BeiGene Tumor Immunity PD-1 Inhibitors Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 138. BeiGene Business Overview
Table 139. BeiGene Recent Developments
Table 140. Global Tumor Immunity PD-1 Inhibitors Sales Forecast by Region (2026-2035) & (K MT)
Table 141. Global Tumor Immunity PD-1 Inhibitors Market Size Forecast by Region (2026-2035) & (M USD)
Table 142. North America Tumor Immunity PD-1 Inhibitors Sales Forecast by Country (2026-2035) & (K MT)
Table 143. North America Tumor Immunity PD-1 Inhibitors Market Size Forecast by Country (2026-2035) & (M USD)
Table 144. Europe Tumor Immunity PD-1 Inhibitors Sales Forecast by Country (2026-2035) & (K MT)
Table 145. Europe Tumor Immunity PD-1 Inhibitors Market Size Forecast by Country (2026-2035) & (M USD)
Table 146. Asia Pacific Tumor Immunity PD-1 Inhibitors Sales Forecast by Region (2026-2035) & (K MT)
Table 147. Asia Pacific Tumor Immunity PD-1 Inhibitors Market Size Forecast by Region (2026-2035) & (M USD)
Table 148. South America Tumor Immunity PD-1 Inhibitors Sales Forecast by Country (2026-2035) & (K MT)
Table 149. South America Tumor Immunity PD-1 Inhibitors Market Size Forecast by Country (2026-2035) & (M USD)
Table 150. Middle East and Africa Tumor Immunity PD-1 Inhibitors Sales Forecast by Country (2026-2035) & (Units)
Table 151. Middle East and Africa Tumor Immunity PD-1 Inhibitors Market Size Forecast by Country (2026-2035) & (M USD)
Table 152. Global Tumor Immunity PD-1 Inhibitors Sales Forecast by Type (2026-2035) & (K MT)
Table 153. Global Tumor Immunity PD-1 Inhibitors Market Size Forecast by Type (2026-2035) & (M USD)
Table 154. Global Tumor Immunity PD-1 Inhibitors Price Forecast by Type (2026-2035) & (USD/KG)
Table 155. Global Tumor Immunity PD-1 Inhibitors Sales (K MT) Forecast by Application (2026-2035)
Table 156. Global Tumor Immunity PD-1 Inhibitors Market Size Forecast by Application (2026-2035) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Tumor Immunity PD-1 Inhibitors Market Size by Type (M USD)
Table 4. Global Tumor Immunity PD-1 Inhibitors Market Size by Application
Table 5. Tumor Immunity PD-1 Inhibitors Market Size Comparison by Region (M USD)
Table 6. Global Tumor Immunity PD-1 Inhibitors Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Tumor Immunity PD-1 Inhibitors Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Tumor Immunity PD-1 Inhibitors Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Immunity PD-1 Inhibitors as of 2025)
Table 11. Global Market Tumor Immunity PD-1 Inhibitors Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers’ Manufacturing Sites, Areas Served
Table 13. Manufacturers’ Product Type
Table 14. Global Tumor Immunity PD-1 Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Tumor Immunity PD-1 Inhibitors Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Tumor Immunity PD-1 Inhibitors Sales by Type (K MT)
Table 27. Global Tumor Immunity PD-1 Inhibitors Market Size by Type (M USD)
Table 28. Global Tumor Immunity PD-1 Inhibitors Sales (K MT) by Type (2020-2025)
Table 29. Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Type (2020-2025)
Table 30. Global Tumor Immunity PD-1 Inhibitors Market Size (M USD) by Type (2020-2025)
Table 31. Global Tumor Immunity PD-1 Inhibitors Market Share by Type (2020-2025)
Table 32. Global Tumor Immunity PD-1 Inhibitors Price (USD/KG) by Type (2020-2025)
Table 33. Global Tumor Immunity PD-1 Inhibitors Sales (K MT) by Application
Table 34. Global Tumor Immunity PD-1 Inhibitors Market Size by Application
Table 35. Global Tumor Immunity PD-1 Inhibitors Sales by Application (2020-2025) & (K MT)
Table 36. Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Application (2020-2025)
Table 37. Global Tumor Immunity PD-1 Inhibitors Market Size by Application (2020-2025) & (M USD)
Table 38. Global Tumor Immunity PD-1 Inhibitors Market Share by Application (2020-2025)
Table 39. Global Tumor Immunity PD-1 Inhibitors Sales Growth Rate by Application (2020-2025)
Table 40. Global Tumor Immunity PD-1 Inhibitors Sales by Region (2020-2025) & (K MT)
Table 41. Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Region (2020-2025)
Table 42. Global Tumor Immunity PD-1 Inhibitors Market Size by Region (2020-2025) & (M USD)
Table 43. Global Tumor Immunity PD-1 Inhibitors Market Size by Region (2020-2025)
Table 44. North America Tumor Immunity PD-1 Inhibitors Sales by Country (2020-2025) & (K MT)
Table 45. North America Tumor Immunity PD-1 Inhibitors Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Tumor Immunity PD-1 Inhibitors Sales by Country (2020-2025) & (K MT)
Table 47. Europe Tumor Immunity PD-1 Inhibitors Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Tumor Immunity PD-1 Inhibitors Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific Tumor Immunity PD-1 Inhibitors Market Size by Region (2020-2025) & (M USD)
Table 50. South America Tumor Immunity PD-1 Inhibitors Sales by Country (2020-2025) & (K MT)
Table 51. South America Tumor Immunity PD-1 Inhibitors Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Tumor Immunity PD-1 Inhibitors Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa Tumor Immunity PD-1 Inhibitors Market Size by Region (2020-2025) & (M USD)
Table 54. Global Tumor Immunity PD-1 Inhibitors Production (K MT) by Region(2020-2025)
Table 55. Global Tumor Immunity PD-1 Inhibitors Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Tumor Immunity PD-1 Inhibitors Revenue Market Share by Region (2020-2025)
Table 57. Global Tumor Immunity PD-1 Inhibitors Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America Tumor Immunity PD-1 Inhibitors Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe Tumor Immunity PD-1 Inhibitors Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan Tumor Immunity PD-1 Inhibitors Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China Tumor Immunity PD-1 Inhibitors Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. Merck Basic Information
Table 63. Merck Tumor Immunity PD-1 Inhibitors Product Overview
Table 64. Merck Tumor Immunity PD-1 Inhibitors Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. Merck Business Overview
Table 66. Merck SWOT Analysis
Table 67. Merck Recent Developments
Table 68. Novartis Basic Information
Table 69. Novartis Tumor Immunity PD-1 Inhibitors Product Overview
Table 70. Novartis Tumor Immunity PD-1 Inhibitors Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. Novartis Business Overview
Table 72. Novartis SWOT Analysis
Table 73. Novartis Recent Developments
Table 74. Sumitomo Dainippon Pharma Basic Information
Table 75. Sumitomo Dainippon Pharma Tumor Immunity PD-1 Inhibitors Product Overview
Table 76. Sumitomo Dainippon Pharma Tumor Immunity PD-1 Inhibitors Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. Sumitomo Dainippon Pharma Business Overview
Table 78. Sumitomo Dainippon Pharma SWOT Analysis
Table 79. Sumitomo Dainippon Pharma Recent Developments
Table 80. Genentech (Roche) Basic Information
Table 81. Genentech (Roche) Tumor Immunity PD-1 Inhibitors Product Overview
Table 82. Genentech (Roche) Tumor Immunity PD-1 Inhibitors Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. Genentech (Roche) Business Overview
Table 84. Genentech (Roche) Recent Developments
Table 85. AstraZeneca Basic Information
Table 86. AstraZeneca Tumor Immunity PD-1 Inhibitors Product Overview
Table 87. AstraZeneca Tumor Immunity PD-1 Inhibitors Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 88. AstraZeneca Business Overview
Table 89. AstraZeneca Recent Developments
Table 90. Pfizer Basic Information
Table 91. Pfizer Tumor Immunity PD-1 Inhibitors Product Overview
Table 92. Pfizer Tumor Immunity PD-1 Inhibitors Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. Pfizer Business Overview
Table 94. Pfizer Recent Developments
Table 95. GSK Basic Information
Table 96. GSK Tumor Immunity PD-1 Inhibitors Product Overview
Table 97. GSK Tumor Immunity PD-1 Inhibitors Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. GSK Business Overview
Table 99. GSK Recent Developments
Table 100. Regeneron Pharmaceuticals Basic Information
Table 101. Regeneron Pharmaceuticals Tumor Immunity PD-1 Inhibitors Product Overview
Table 102. Regeneron Pharmaceuticals Tumor Immunity PD-1 Inhibitors Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 103. Regeneron Pharmaceuticals Business Overview
Table 104. Regeneron Pharmaceuticals Recent Developments
Table 105. Eli Lilly Basic Information
Table 106. Eli Lilly Tumor Immunity PD-1 Inhibitors Product Overview
Table 107. Eli Lilly Tumor Immunity PD-1 Inhibitors Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 108. Eli Lilly Business Overview
Table 109. Eli Lilly Recent Developments
Table 110. Jiangsu Hengrui Pharmaceuticals Basic Information
Table 111. Jiangsu Hengrui Pharmaceuticals Tumor Immunity PD-1 Inhibitors Product Overview
Table 112. Jiangsu Hengrui Pharmaceuticals Tumor Immunity PD-1 Inhibitors Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 113. Jiangsu Hengrui Pharmaceuticals Business Overview
Table 114. Jiangsu Hengrui Pharmaceuticals Recent Developments
Table 115. Curis Inc. Basic Information
Table 116. Curis Inc. Tumor Immunity PD-1 Inhibitors Product Overview
Table 117. Curis Inc. Tumor Immunity PD-1 Inhibitors Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 118. Curis Inc. Business Overview
Table 119. Curis Inc. Recent Developments
Table 120. Bristol-Myers Squibb Basic Information
Table 121. Bristol-Myers Squibb Tumor Immunity PD-1 Inhibitors Product Overview
Table 122. Bristol-Myers Squibb Tumor Immunity PD-1 Inhibitors Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 123. Bristol-Myers Squibb Business Overview
Table 124. Bristol-Myers Squibb Recent Developments
Table 125. Junshi Biosciences Basic Information
Table 126. Junshi Biosciences Tumor Immunity PD-1 Inhibitors Product Overview
Table 127. Junshi Biosciences Tumor Immunity PD-1 Inhibitors Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 128. Junshi Biosciences Business Overview
Table 129. Junshi Biosciences Recent Developments
Table 130. Innovent Biologics Basic Information
Table 131. Innovent Biologics Tumor Immunity PD-1 Inhibitors Product Overview
Table 132. Innovent Biologics Tumor Immunity PD-1 Inhibitors Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 133. Innovent Biologics Business Overview
Table 134. Innovent Biologics Recent Developments
Table 135. BeiGene Basic Information
Table 136. BeiGene Tumor Immunity PD-1 Inhibitors Product Overview
Table 137. BeiGene Tumor Immunity PD-1 Inhibitors Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 138. BeiGene Business Overview
Table 139. BeiGene Recent Developments
Table 140. Global Tumor Immunity PD-1 Inhibitors Sales Forecast by Region (2026-2035) & (K MT)
Table 141. Global Tumor Immunity PD-1 Inhibitors Market Size Forecast by Region (2026-2035) & (M USD)
Table 142. North America Tumor Immunity PD-1 Inhibitors Sales Forecast by Country (2026-2035) & (K MT)
Table 143. North America Tumor Immunity PD-1 Inhibitors Market Size Forecast by Country (2026-2035) & (M USD)
Table 144. Europe Tumor Immunity PD-1 Inhibitors Sales Forecast by Country (2026-2035) & (K MT)
Table 145. Europe Tumor Immunity PD-1 Inhibitors Market Size Forecast by Country (2026-2035) & (M USD)
Table 146. Asia Pacific Tumor Immunity PD-1 Inhibitors Sales Forecast by Region (2026-2035) & (K MT)
Table 147. Asia Pacific Tumor Immunity PD-1 Inhibitors Market Size Forecast by Region (2026-2035) & (M USD)
Table 148. South America Tumor Immunity PD-1 Inhibitors Sales Forecast by Country (2026-2035) & (K MT)
Table 149. South America Tumor Immunity PD-1 Inhibitors Market Size Forecast by Country (2026-2035) & (M USD)
Table 150. Middle East and Africa Tumor Immunity PD-1 Inhibitors Sales Forecast by Country (2026-2035) & (Units)
Table 151. Middle East and Africa Tumor Immunity PD-1 Inhibitors Market Size Forecast by Country (2026-2035) & (M USD)
Table 152. Global Tumor Immunity PD-1 Inhibitors Sales Forecast by Type (2026-2035) & (K MT)
Table 153. Global Tumor Immunity PD-1 Inhibitors Market Size Forecast by Type (2026-2035) & (M USD)
Table 154. Global Tumor Immunity PD-1 Inhibitors Price Forecast by Type (2026-2035) & (USD/KG)
Table 155. Global Tumor Immunity PD-1 Inhibitors Sales (K MT) Forecast by Application (2026-2035)
Table 156. Global Tumor Immunity PD-1 Inhibitors Market Size Forecast by Application (2026-2035) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Tumor Immunity PD-1 Inhibitors
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Tumor Immunity PD-1 Inhibitors Market Size (M USD), 2025-2035
Figure 5. Global Tumor Immunity PD-1 Inhibitors Market Size (M USD) (2020-2035)
Figure 6. Global Tumor Immunity PD-1 Inhibitors Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Tumor Immunity PD-1 Inhibitors Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Tumor Immunity PD-1 Inhibitors Product Life Cycle
Figure 13. Tumor Immunity PD-1 Inhibitors Sales Share by Manufacturers in 2025
Figure 14. Global Tumor Immunity PD-1 Inhibitors Revenue Share by Manufacturers in 2025
Figure 15. Tumor Immunity PD-1 Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Tumor Immunity PD-1 Inhibitors Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Tumor Immunity PD-1 Inhibitors Revenue in 2025
Figure 18. Industry Chain Map of Tumor Immunity PD-1 Inhibitors
Figure 19. Global Tumor Immunity PD-1 Inhibitors Market PEST Analysis
Figure 20. Global Tumor Immunity PD-1 Inhibitors Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Tumor Immunity PD-1 Inhibitors Market Share by Type
Figure 27. Sales Market Share of Tumor Immunity PD-1 Inhibitors by Type (2020-2025)
Figure 28. Sales Market Share of Tumor Immunity PD-1 Inhibitors by Type in 2025
Figure 29. Market Share of Tumor Immunity PD-1 Inhibitors by Type (2020-2025)
Figure 30. Market Share of Tumor Immunity PD-1 Inhibitors by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Tumor Immunity PD-1 Inhibitors Market Share by Application
Figure 33. Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Application (2020-2025)
Figure 34. Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Application in 2025
Figure 35. Global Tumor Immunity PD-1 Inhibitors Market Share by Application (2020-2025)
Figure 36. Global Tumor Immunity PD-1 Inhibitors Market Share by Application in 2025
Figure 37. Global Tumor Immunity PD-1 Inhibitors Sales Growth Rate by Application (2020-2025)
Figure 38. Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Region (2020-2025)
Figure 39. Global Tumor Immunity PD-1 Inhibitors Market Size by Region (2020-2025)
Figure 40. North America Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Tumor Immunity PD-1 Inhibitors Sales Market Share by Country in 2024
Figure 43. North America Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Tumor Immunity PD-1 Inhibitors Market Size by Country in 2024
Figure 45. U.S. Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Tumor Immunity PD-1 Inhibitors Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Tumor Immunity PD-1 Inhibitors Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Tumor Immunity PD-1 Inhibitors Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Tumor Immunity PD-1 Inhibitors Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Tumor Immunity PD-1 Inhibitors Sales Market Share by Country in 2024
Figure 53. Europe Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Tumor Immunity PD-1 Inhibitors Market Size by Country in 2024
Figure 55. Germany Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Tumor Immunity PD-1 Inhibitors Sales Market Share by Region in 2024
Figure 67. Asia Pacific Tumor Immunity PD-1 Inhibitors Market Size by Region in 2024
Figure 68. China Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (K MT)
Figure 79. South America Tumor Immunity PD-1 Inhibitors Sales Market Share by Country in 2024
Figure 80. South America Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (M USD)
Figure 81. South America Tumor Immunity PD-1 Inhibitors Market Size by Country in 2024
Figure 82. Brazil Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Tumor Immunity PD-1 Inhibitors Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Tumor Immunity PD-1 Inhibitors Market Size by Region in 2024
Figure 92. Saudi Arabia Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Tumor Immunity PD-1 Inhibitors Production Market Share by Region (2020-2025)
Figure 103. North America Tumor Immunity PD-1 Inhibitors Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Tumor Immunity PD-1 Inhibitors Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Tumor Immunity PD-1 Inhibitors Production (K MT) Growth Rate (2020-2025)
Figure 106. China Tumor Immunity PD-1 Inhibitors Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Tumor Immunity PD-1 Inhibitors Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global Tumor Immunity PD-1 Inhibitors Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Tumor Immunity PD-1 Inhibitors Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Tumor Immunity PD-1 Inhibitors Market Share Forecast by Type (2026-2035)
Figure 111. Global Tumor Immunity PD-1 Inhibitors Sales Forecast by Application (2026-2035)
Figure 112. Global Tumor Immunity PD-1 Inhibitors Market Share Forecast by Application (2026-2035)
Figure 1. Product Picture of Tumor Immunity PD-1 Inhibitors
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Tumor Immunity PD-1 Inhibitors Market Size (M USD), 2025-2035
Figure 5. Global Tumor Immunity PD-1 Inhibitors Market Size (M USD) (2020-2035)
Figure 6. Global Tumor Immunity PD-1 Inhibitors Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Tumor Immunity PD-1 Inhibitors Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Tumor Immunity PD-1 Inhibitors Product Life Cycle
Figure 13. Tumor Immunity PD-1 Inhibitors Sales Share by Manufacturers in 2025
Figure 14. Global Tumor Immunity PD-1 Inhibitors Revenue Share by Manufacturers in 2025
Figure 15. Tumor Immunity PD-1 Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Tumor Immunity PD-1 Inhibitors Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Tumor Immunity PD-1 Inhibitors Revenue in 2025
Figure 18. Industry Chain Map of Tumor Immunity PD-1 Inhibitors
Figure 19. Global Tumor Immunity PD-1 Inhibitors Market PEST Analysis
Figure 20. Global Tumor Immunity PD-1 Inhibitors Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Tumor Immunity PD-1 Inhibitors Market Share by Type
Figure 27. Sales Market Share of Tumor Immunity PD-1 Inhibitors by Type (2020-2025)
Figure 28. Sales Market Share of Tumor Immunity PD-1 Inhibitors by Type in 2025
Figure 29. Market Share of Tumor Immunity PD-1 Inhibitors by Type (2020-2025)
Figure 30. Market Share of Tumor Immunity PD-1 Inhibitors by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Tumor Immunity PD-1 Inhibitors Market Share by Application
Figure 33. Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Application (2020-2025)
Figure 34. Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Application in 2025
Figure 35. Global Tumor Immunity PD-1 Inhibitors Market Share by Application (2020-2025)
Figure 36. Global Tumor Immunity PD-1 Inhibitors Market Share by Application in 2025
Figure 37. Global Tumor Immunity PD-1 Inhibitors Sales Growth Rate by Application (2020-2025)
Figure 38. Global Tumor Immunity PD-1 Inhibitors Sales Market Share by Region (2020-2025)
Figure 39. Global Tumor Immunity PD-1 Inhibitors Market Size by Region (2020-2025)
Figure 40. North America Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Tumor Immunity PD-1 Inhibitors Sales Market Share by Country in 2024
Figure 43. North America Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Tumor Immunity PD-1 Inhibitors Market Size by Country in 2024
Figure 45. U.S. Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Tumor Immunity PD-1 Inhibitors Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Tumor Immunity PD-1 Inhibitors Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Tumor Immunity PD-1 Inhibitors Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Tumor Immunity PD-1 Inhibitors Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Tumor Immunity PD-1 Inhibitors Sales Market Share by Country in 2024
Figure 53. Europe Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Tumor Immunity PD-1 Inhibitors Market Size by Country in 2024
Figure 55. Germany Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Tumor Immunity PD-1 Inhibitors Sales Market Share by Region in 2024
Figure 67. Asia Pacific Tumor Immunity PD-1 Inhibitors Market Size by Region in 2024
Figure 68. China Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (K MT)
Figure 79. South America Tumor Immunity PD-1 Inhibitors Sales Market Share by Country in 2024
Figure 80. South America Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (M USD)
Figure 81. South America Tumor Immunity PD-1 Inhibitors Market Size by Country in 2024
Figure 82. Brazil Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Tumor Immunity PD-1 Inhibitors Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Tumor Immunity PD-1 Inhibitors Market Size by Region in 2024
Figure 92. Saudi Arabia Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Tumor Immunity PD-1 Inhibitors Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Tumor Immunity PD-1 Inhibitors Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Tumor Immunity PD-1 Inhibitors Production Market Share by Region (2020-2025)
Figure 103. North America Tumor Immunity PD-1 Inhibitors Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Tumor Immunity PD-1 Inhibitors Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Tumor Immunity PD-1 Inhibitors Production (K MT) Growth Rate (2020-2025)
Figure 106. China Tumor Immunity PD-1 Inhibitors Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Tumor Immunity PD-1 Inhibitors Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global Tumor Immunity PD-1 Inhibitors Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Tumor Immunity PD-1 Inhibitors Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Tumor Immunity PD-1 Inhibitors Market Share Forecast by Type (2026-2035)
Figure 111. Global Tumor Immunity PD-1 Inhibitors Sales Forecast by Application (2026-2035)
Figure 112. Global Tumor Immunity PD-1 Inhibitors Market Share Forecast by Application (2026-2035)
